Proteomics Study of Gastric Bypass Surgery to Treat Type 2 Diabetes Mellitus
Serum Proteomics Research in Bypassing Surgery to Treat Type 2 Diabetes in China
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Diabetes Mellitus is a major global problem which responsibles for 4.6 million deaths each year without effective therapy methods. Recently，researchers showed that type 2 diabetes mellitus can be partly reversed by gastric bypassing surgery. However, surgeons are still not clear how to chose the proper diabetes patients for surgery as the mechanism is still not clear, and the remission rate of diabetes mellitus is not the same among different surgical procedures.
This study will enroll type 2 diabetes mellitus patients follwing Roux-en-Y gastric bypassing surgery and obese persons without type 2 diabetes surgery. The defferent expressions of serum proteins of obese persons without type 2 diabetes and type 2 diabetes patients following gastric bypassing surgery after 10 days or 3 months were detected by serum proteomics. Blood samples and urine will be taken prior to surgery, 10 days after surgery and 3 months after surgery. The long term prognosis of diabetes mellitus for 1 years and the remission rate of diabetes of patients will be evaluated.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Henan
-
Luoyang, Henan, Kina, 471000
- No. 150 Central hospital of Chinese People's Liberation Army
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- patients diagnosed as type 2 diabetes are planning to have Roux-en-Y gastric bypass
- age:18-65yr
- HbAlc>8%
Exclusion Criteria:
- diabetes (applies for control patients)
- chronic inflammatory disease
- malignant disease
- pregnancy
- prior gastric, duodenal, proximal jejunal surgery or pancreas resection
- current use of thiazolidinediones
- treatment with incretin mimetics or DPP IV inhibitors in the prior 3 months
- HbAlc<8%
- any condition felt by the investigator to interfere with ability to complete the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
type 2 diabetes patients with gastric bypass surgery.
Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
|
|
Weight matched non-operated controls
Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
different proteins detected between obese persons, type 2 diabetes patients prior to surgery, 10 days after surgery and 3 months after surgery.
Tidsramme: base line to 3 months
|
base line to 3 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
evaluating the change in glucose between the baseline evaluation and the follow-up evaluation.
Tidsramme: 1 year
|
1 year
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 150CTSX001
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .